Showing Results for
- Academic Journals (13)
Search Results
- 13
Academic Journals
- 13
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedThe pharmaceutical industry registered US $800 million ([euro]744 million) in sales in 2020 and is forecast to grow at a 7.6% compound annual growth rate through 2026, according to Pharmaceutical Manufacturing Trends...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedFor more than a decade, manufacturers have been exploring new ways to improve the efficiency of cell therapy production to make it more cost-effective and accessible to those in need. Many companies have been working in...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedQ Creating a contamination control strategy (CCS) is now a requirement defined in Annex 1 of the European good manufacturing practice regulations (1). The document does not describe how to create such a strategy. Can you...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedThe COVID-19 pandemic remains a global threat due to continued transmission of the SARS-CoV-2 virus despite the availability of several intramuscular vaccines. Vaccines administered intramuscularly via injection can...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedOn 11 Aug. 2020, the European Commission (EC) published its evaluation on the legislation for medicines for rare diseases and for children (1). This marked the first comprehensive evaluation of the Orphan Regulation...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedEnvironmentally conscious business practices are much more prominent nowadays in many parts of the world and across all industries. For Europe, in particular, a common goal that has been set out by national governments...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedFor the past 10 years, Clarivate has published its Drugs to Watch report annually, highlighting therapies that are deemed to have blockbuster potential (i.e., achieving sales of more than US$1 billion [[euro]931 million]...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedIn Pharmaceutical Technology Europe's annual employment survey, respondents have been asked a consistent set of questions year to year to build some inherent statistical confidence in the replies. In this year's survey,...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedEvery year, the editors of Pharmaceutical Technology Europe conduct a survey (1) designed to measure the state of the bio/pharma industry. More specifically, the survey assesses various employment metrics, thoughts on...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedWithin the bio/pharma industry, there is a certain expectation for companies to maintain required levels of cleanliness within their facilities to ensure products that are manufactured are at minimal risk of...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedWhen it comes to solid vs. semi-solid drugs, there are many considerations for manufacturers to take in regards to the process in which the end product is made. While solid dosage drugs may be easier to manufacture, they...
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedPredictive analysis is a tricky business--it's difficult to find experts who can not only thoroughly document trends of the past year, but also understand the underlying market forces at work that are causing them....
-
From:Pharmaceutical Technology Europe (Vol. 35, Issue 1) Peer-ReviewedThe bio/pharmaceutical industry has made it through 2022--a year that started off with the unrelenting COVID-19 pandemic, continued th Russia's invasion of Ukraine, and culminated in global economic struggles--evolving...